MAKING SCIENCE GROUP, SA (the "**Company**", the "**Company**", the "**Group**", or "**Making Science**") pursuant to the provisions of Article 17 of Regulation (EU) No. 596 / 2014 on market abuse and in article 228 of the revised text of the Securities Market Law, approved by Royal Legislative Decree 4/2015, of October 23, and related provisions, as well as in Circular 3/2020 of the BME Growth segment of BME MTF Equity, hereby discloses the following:

PRIVILEGED INFORMATION

On October 8, Making Science registered its first bond issuance under the "Making Science Group, SA 2021 Fixed Income Program" (the "**Bond Program**") for a nominal value of 12 million euros. There are still up to 18 million euros remaining and available from the entire 30 million euros Bond Program.

The funds obtained within the framework of the Bond Program are intended to finance the M&A activity in line with the Making Science growth and internationalization strategy for the period 2021 and 2022.

The bond issuance has a maturity of 3 years and an annual interest rate of 5.5% plus an additional 0.05% per annum linked to the level of international sales and an additional margin up to 1.95% per annum based on the consolidated proforma recurring EBITDA of 2023 (for Each increase of 238.5 thousand euros in the Proforma Consolidated Recurring EBITDA for fiscal year 2023, from a minimum of 16.8 million euros and up to a maximum of 21.6 million euros, will accrue interest of 0.0975% on annual basis).

The Bond Program has a credit rating ("rating") issued by AXESOR (a rating agency certified by ESMA at European level) of BB with a positive outlook.

Making Science has received requests for subscription of bonds 33% higher than the amount of the issuance.

Renta 4 Banco has participated in the process as director and bookrunner; EBN as bookrunner and Ramón y Cajal as legal advisor.

We remain at your disposal for any further clarification.

Yours sincerely,

CEO of Making Science Group, SA

José Antonio Martínez Aguilar